Fibromyalgia is a real, physically measurable condition. It was recognized as a disease by the American Medical Association in 1987 and by the World Health Organization in 1992. Brain scans, spinal fluid analysis, and skin biopsies all reveal objective differences between people with fibromyalgia and healthy controls. The confusion around whether it’s “mental” comes from the fact that fibromyalgia involves the nervous system, which sits at the intersection of body and mind, and because depression and anxiety frequently accompany it.
What Happens in the Nervous System
The core problem in fibromyalgia is something called central sensitization: the central nervous system amplifies pain signals, essentially turning up the volume on sensory input. In a healthy nervous system, a light touch on the arm registers as pressure. In someone with fibromyalgia, that same touch can register as pain, a phenomenon known as allodynia. Similarly, mildly painful stimuli feel far more intense than they should, which is called hyperalgesia. The pain receptive field also expands, meaning more areas of the body become sensitive over time.
This amplification has a chemical basis. Four independent studies have found that people with fibromyalgia have roughly three times the normal concentration of substance P in their cerebrospinal fluid. Substance P is a neurotransmitter that carries pain signals. Glutamate, another excitatory brain chemical, is also elevated, both in spinal fluid and directly within brain tissue. These aren’t subtle or ambiguous findings. They represent measurable, reproducible differences in how the nervous system processes information.
What Brain Imaging Shows
Functional MRI studies comparing fibromyalgia patients to healthy controls show distinct patterns of brain activity during pain. When exposed to the same painful stimulus, people with fibromyalgia show increased responsiveness in the dorsal anterior cingulate cortex and supplementary motor area, regions involved in processing pain intensity and preparing physical responses to threats. Their brains also recruit the right insula more heavily, a region tied to how the body perceives internal sensations. Healthy controls, by contrast, rely more on prefrontal areas associated with regulating and dampening pain.
In practical terms, this means fibromyalgia isn’t a case of someone imagining pain. Their brains are genuinely processing stimuli differently, and the pattern is consistent enough across studies to show up in meta-analyses pooling data from many research groups.
Physical Evidence You Can See Under a Microscope
One of the most compelling pieces of evidence comes from skin biopsies. About 50% of women with fibromyalgia have reduced skin innervation, meaning they have fewer small nerve fibers in their skin than expected. A broader analysis found reduced nerve fiber density at various biopsy sites in 63% of fibromyalgia patients, compared to just 18% of healthy controls. For context, only 10% of people with major depressive disorder and pain showed the same reduction, which directly challenges the idea that fibromyalgia is simply depression presenting as physical symptoms.
This type of small fiber pathology is an objective, structural finding. It’s visible under a microscope and countable. It doesn’t depend on the patient reporting their symptoms or a doctor interpreting subjective complaints.
Sleep Disruption Is Measurable Too
People with fibromyalgia consistently report terrible sleep, and polysomnography (overnight sleep monitoring) confirms it. Studies show a pattern called alpha-delta sleep, where fast alpha brain waves intrude into the deep, restorative phases of sleep. This results in shallow, fragmented sleep with more awakenings and less time spent in REM and slow-wave stages. The alpha-delta ratio worsens as the night goes on, meaning sleep quality deteriorates progressively through each sleep cycle.
This isn’t just feeling tired. It’s a documented disruption of sleep architecture that likely feeds back into pain sensitivity, since deep sleep is when the body does most of its tissue repair and pain modulation.
The Relationship With Depression and Anxiety
Here’s where the “mental” question gets more nuanced. About 54% of people with fibromyalgia have clinical symptoms of depression, and roughly 55% have clinical symptoms of anxiety. These are the highest rates of any chronic pain condition. When looking specifically at diagnosed major depressive disorder, the rate is around 38%, and for generalized anxiety disorder, about 33%.
These numbers are high, but they don’t mean fibromyalgia is a psychiatric condition in disguise. Chronic pain of any kind raises the risk of depression and anxiety. Living with persistent, poorly understood pain that others often dismiss takes a psychological toll. Research on chronic pain and mental health explicitly notes that the direction of the relationship varies by pain type, and the coexistence of two conditions doesn’t mean one caused the other. Roughly half of fibromyalgia patients don’t have significant depression at all, which would be hard to explain if the condition were purely psychological.
It’s more accurate to think of fibromyalgia as a nervous system disorder that frequently brings mental health consequences along with it, much the way chronic heart disease or diabetes increases depression risk without being considered mental illnesses.
How It’s Formally Classified
The WHO’s International Classification of Diseases places fibromyalgia under “chronic primary pain,” specifically as a form of widespread chronic primary pain. This classification defines it as pain persisting or recurring for more than three months, associated with significant emotional distress or functional disability, that can’t be better explained by another condition. Biological findings may or may not be present for the diagnosis, which reflects the reality that standard blood tests and X-rays don’t capture what’s happening at the nervous system level.
Diagnosis currently relies on a standardized scoring system. Clinicians assess a Widespread Pain Index, which maps how many body areas are affected, alongside a Symptom Severity scale that accounts for fatigue, sleep problems, and cognitive difficulties. These tools replaced the old tender-point exam and don’t require a specialist to administer.
Why Treatments Target the Nervous System
The medications approved for fibromyalgia work by directly altering nervous system chemistry, which reinforces that the condition is rooted in how the body processes signals. One class of medication reduces the release of excitatory neurotransmitters like glutamate and substance P by blocking calcium channels on nerve endings, essentially calming overactive nerve signaling. Another class increases levels of serotonin and norepinephrine, two chemicals that help regulate pain pathways, and is also believed to inhibit substance P.
These aren’t painkillers in the traditional sense. They don’t block pain at the site of injury the way ibuprofen does. Instead, they recalibrate how the central nervous system handles incoming signals. The fact that they reduce pain, fatigue, and cognitive symptoms (often called “fibro fog”) through nervous system mechanisms is itself evidence that fibromyalgia is a disorder of neural processing, not imagination.
Exercise, cognitive behavioral therapy, and sleep interventions also show benefit, not because the condition is “all in your head,” but because all of these influence how the nervous system functions. Aerobic exercise, for instance, triggers the release of the body’s own pain-dampening chemicals and can gradually reduce central sensitization over time.